QIAGEN launches Oncology Molecular Profiling Services in Europe
• QIAGEN Clinical Insights (QCI) fully integrates N-of-One product into portfolio
• QCI Precision Insights now includes ESMO guidelines and EMA approved oncology drugs
• Platform launches in Europe for molecular pathologists, oncologists, and medical geneticists
Redwood City, California, and Hilden, Germany, January 15, 2020 – QIAGEN today announced the launch of QCI Precision Insights in Europe, with the inclusion of the
European Society for Medical Oncology (ESMO) guidelines and
European Medicines Agency (EMA) approved oncology drugs catalogue.
QCI Precision Insights is a clinical interpretation service provided by a team of molecular biologists and oncologists who translate molecular data specific to each patient into state-of-the-art clinical insights and therapeutic options. Capable of rapidly interpreting any size panel on any testing platform, QCI Precision Insights now enables molecular pathologists and oncologists in Europe to confidently match complex genomic test data to relevant, geographically-matched treatment options in minutes for evidence-based, individualized treatment recommendations in record time.
”With the growing demand for molecular testing in the clinic, there is a continuous struggle to keep pace. With the finalized integration of N-of-One and their somatic interpretation service into the QCI product line we can now meet this demand” said Jonathan Sheldon, Senior Vice President of QIAGEN Digital Insights. “Molecular pathologists can now off-load interpretation work and reduce clinical test interpretation time by as much as 85%. So far, over 175,000 oncology cases have been processed by QCI Precision Insights, and I’m excited to see how Europe will embrace this new opportunity to transform the way molecular pathologists intersect with the cancer care continuum.”
The QCI portfolio helps molecular pathologists, oncologists, and medical geneticists uncover critical and timely genomics insights for informed and empowered clinical decision making. Connected to QCI knowledgebase, the platform has processed over 1.6 million molecular profiling cases across somatic and germline indications, giving users access to a rich set of unpublished real-world data for greater precision in trial and treatment matching.
The QIAGEN Knowledge Base is the only manually-curated knowledgebase in the world supporting over 76,000 disease classes with over 20 million clinical findings and weekly updates to clinical trial registries, approved therapies, and published literature.
QCI Precision Insights offers:
- Variant/gene-specific information with direct reference to EMA drug approvals and ESMO guidelines
- EMA approved drug summaries and approved indications
- ESMO clinical practice guidelines
- Up-to-date treatments approved by EMA
- Demographically relevant European clinical trials
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of September 30, 2019, QIAGEN employed approximately 5,200 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
Forward Looking StatementCertain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, launches, regulatory submissions, collaborations, markets, strategy, taxes or operating results, including without limitation its expected net sales, net sales of particular products (including anticipated sales of its QuantiFERON latent TB Test, its portfolio of next generation sequencing solutions and QIAstat-Dx), adjusted net sales, adjusted diluted earnings per share results, product launches (including anticipated launches of digital PCR products, a new version of its QuantiFERON-TB test, QuantiFERON-TB Access, the QIAstat-Dx panel for respiratory conditions and a CE-IVD marked panel for meningitis), placements of QIAsymphony modular PCR instruments, improvements in operating and financial leverage, currency movements against the U.S. dollar, and plans for investment in its portfolio and share repurchase commitments, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics); variability of operating results and allocations between customer classes; the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; and the other factors discussed under the heading “Risk Factors” contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).